Knuff & Co LLC cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 59.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,380 shares of the company's stock after selling 12,417 shares during the quarter. Knuff & Co LLC's holdings in Moderna were worth $833,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Arlington Trust Co LLC boosted its holdings in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock valued at $29,000 after purchasing an additional 290 shares during the period. GPS Wealth Strategies Group LLC increased its stake in Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company's stock worth $53,000 after acquiring an additional 180 shares during the last quarter. Archer Investment Corp raised its holdings in shares of Moderna by 71.2% in the 3rd quarter. Archer Investment Corp now owns 534 shares of the company's stock valued at $55,000 after acquiring an additional 222 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Moderna by 44.9% during the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company's stock valued at $58,000 after acquiring an additional 175 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in shares of Moderna by 408.3% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company's stock worth $63,000 after purchasing an additional 490 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.
Moderna Trading Down 0.5 %
Shares of MRNA stock traded down $0.59 during mid-day trading on Friday, reaching $125.00. The stock had a trading volume of 4,513,133 shares, compared to its average volume of 3,445,723. The firm has a market capitalization of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. The stock's 50-day moving average price is $105.05 and its two-hundred day moving average price is $94.48. The company has a current ratio of 4.03, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79.
Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts' consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna's quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.19 EPS. Equities analysts expect that Moderna, Inc. will post -7.47 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the company's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total transaction of $53,883.20. Following the transaction, the insider now owns 9,267 shares in the company, valued at approximately $917,896.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of Moderna stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock worth $14,822,576 over the last three months. Company insiders own 15.70% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on MRNA. HSBC reiterated a "reduce" rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Royal Bank of Canada raised their price target on Moderna from $125.00 to $135.00 and gave the company an "outperform" rating in a research report on Friday. Canaccord Genuity Group increased their price objective on Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a research report on Friday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Moderna in a report on Thursday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $129.55.
Check Out Our Latest Stock Analysis on MRNA
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
